Vaxcyte (PCVX) Q4 2025 earnings summary

Executive summary

• Achieved significant progress in clinical, manufacturing, and commercial readiness for the PCV franchise, with multiple late-stage trials underway and a robust financial position supporting future milestones.

• Advanced VAX-31 into pivotal phase III trials (OPUS-1, -2, -3) in adults and completed enrollment in the optimized infant phase II study, targeting broader pneumococcal disease coverage.

• Expanded adult Breakthrough Therapy designation for VAX-31 to include pneumonia prevention.

• Resumed development of the Group A Strep vaccine candidate (VAX-A1) following strengthened financials, with phase I adult studies planned for 2026.

• Strengthened leadership team and board with experienced industry executives.

Financial highlights

• Cash, cash equivalents, and investments totaled $2.44 billion as of December 31, 2025, down from $3.13 billion at year-end 2024.

• Raised $632.5 million in net proceeds from a public equity offering in February 2026, further strengthening the balance sheet.

• Net loss for 2025 was $766.6 million, compared to $463.9 million in 2024.

• R&D expenses rose to $794.3 million in 2025 from $476.6 million in 2024, driven by increased development and manufacturing activities.

• Capitalized costs rose in 2025 due to manufacturing facility build-out, expected to decline in 2026 as most costs shift to expenses.

Outlook and guidance

• Expect meaningful increase in total expenses in 2026, primarily from manufacturing and clinical trial expansion for VAX-31.

• Topline data from OPUS-1 Phase 3 adult trial expected in Q4 2026; OPUS-2 and OPUS-3 results and VAX-31 infant Phase 2 topline data expected by mid-2027.

• Plan to initiate phase I study for VAX-A1 (Group A Strep) in adults in 2026.